# Novel miRNAs and their Target Gene Networks from Hippocampi of Rats that Performed Regular Exercise: An *In Silico* Study

Marla A. Endriga<sup>1</sup>, Rhey Ian N. Buluag<sup>1</sup>, Jon Sithli P. Mendoza<sup>1</sup>, and Custer C. Deocaris<sup>2\*</sup>

 <sup>1</sup>Department of Biology, College of Arts and Sciences, University of the Philippines, 1000 Ermita, Manila, Philippines
<sup>2</sup>Laboratory of Exercise Biochemistry, Institute of Health and Sports Sciences, University of Tsukuba, 1-1-1 Tennoudai, Tsukuba Ibaraki 305-8574, Japan

MicroRNAs (miRNAs) have been previously described to regulate gene expression. To determine whether such non-coding RNA regulates gene activities in the brain as a consequence of regular exercise, expressed sequence tags (ESTs) derived from a related study by one of the authors on the hippocampi of Swiss Wistar rats that were trained to run on a treadmill were subjected to a computational analysis. Three putative miRNAs homologous to mmu-miR-574-5p and rno-miR-297 have been detected and their possible brain-specific target genes were predicted. Ingenuity Pathways Analysis (IPA)-generated interactomes of the miRNA target genes underscore the role of non-coding RNA in modulating neurogenesis, neuronal cell death and long-term depression. Our elucidation of some molecular networks mediated by these miRNAs offers insights to the well-established effects of physical activity on learning and memory.

Key Words: interactome, molecular networks, neuroscience, systems biology, treadmill running

#### **INTRODUCTION**

Physical exercise has been proven to be generally good for the health. It is widely accepted that regular physical activity can contribute to a reduction in the incidence of obesity (Welk & Blair 2000), cardiovascular disease, and osteoporosis (Kemper et al. 2000). It has also been shown that physical exercise has salutary effects on brain function: ameliorating age-associated cognitive losses (Hillman et al. 2006); improving synaptic plasticity, hippocampal neurogenesis, cognition response, and learning (Etnier et al. 1997; van Praag et al. 1999; Colcombe et al. 2006). These effects of running on the brain are mainly associated with changes in gene expression. Molteni et al. (2002) observed from rats that underwent voluntary exercise the up-regulation of brain-derived neurotrophic factor (BDNF) together with those involved in synaptic trafficking (e.g., synapsin I, synaptotagmin and syntaxin), signal transduction pathways (e.g., Calcium/calmodulin-dependent protein kinase II, CaM-KII; mitogen-activated/extracellular signal-regulated protein kinase, MAP-K/ERK I and II; protein kinase C, PKC-D), the glutaminargic systems (N-methyl-Daspartate receptor, NMDAR-2A and NMDAR-2B and excitatory amino acid carrier 1, EAAC1); and down-regulation of genes related to the gamma-aminobutyric (GABA) system (i.e., GABAA receptor, glutamate decarboxylase GAD65). Cavallaro et al. (2002), on the other hand, found differential expression in groups of genes related to memory and learning in mice. Among these are those involved in microtubule formation and cell signaling.

The discovery of microRNAs has opened new vistas in the understanding of gene regulation in recent years. MicroRNAs (miRNAs) are a class of non-coding RNAs

<sup>\*</sup>Corresponding author: cdeocaris@gmail.com

whose products are ~22 nucleotides (nt) long. They play important roles in the regulation of translation and degradation of mRNAs. This is achieved through base pairing to partially complementary sites in the untranslated regions (UTRs) of the mRNA (Griffiths-Jones 2003).

MiRNAs have a unique feature of folding into characteristic hairpin loop structures in their precursor form. The hairpin loop consists of a head (the loop) and a pair of arms. The mature miRNA sequence is located on one arm and the sequence located directly on the other arm is called the miRNA\* sequence (Preall et al. 2006). In this study, it was found through an *in silico* approach that miRNAs may play a role in regulating genes expressed in the brain after chronic exercise on a treadmill.

# MATERIALS AND METHODS

#### Source of Microarray Data

*In silico* analysis was done on a microarray data set derived from 11-week-old male Swiss Wistar rats from one group (n=4-6) that underwent running for 6 weeks on a treadmill (40 m/min per session, 1 hr per session, 5 sessions per week) and from an equal number of animals on a stationary treadmill (negative control). The rats were sacrificed by decapitation three days after the final exercise activity to remove RNA signals that represent acute response to stress.

Total RNA were then extracted from the hippocampi with QIAGEN RNeasy Mini Kit (QIAGEN, MD), and analyzed spectrophotometrically and visually on agarose gel to check the yield and quality. Total RNA from 3 hippocampi (150 ng from each animal) were pooled, labeled with Cy-3 or Cy-5 using the Agilent Low RNA Input Fluorescent Linear Amplification Kit (Agilent) and hybridized on a rat 44K whole genome oligo DNA microarray chip (G4131A, Agilent Technologies, Palo Alto, CA) following the manufacturer's procedure. After washing, the microarrays were scanned using an Agilent Microarray scanner G2565BA. A dye-swapping procedure, where labeling was performed on reverse, was done to remove dye bias.

For detection of differentially expressed genes between control and exercised samples, each slide image was processed using Agilent Feature Extraction ver.8.1.1. This software selected a probe set by rank consistency filter for dye-normalization, and normalization was performed by LOWESS (locally weighted linear regression). Then, genes showing expression change with differences at least 1.5-fold in both dye-swapped slides were selected (Hirano et al. 2008). All animal experiments, following ethical guidelines on animal care and treatment were performed at the Laboratory of Exercise Biochemistry, University of Tsukuba, Japan and microarray analysis was done by the Human Stress Group, National Institute of Industrial Science and Technology (AIST), Japan. A separate paper, which includes, among many others, data from which the ESTs were derived for this paper and which were not shown, is being prepared (Deocaris et al. in preparation).

#### **MicroRNA Identification**

Sequences of the transcriptome data set in the form of ESTs were manually obtained from the NCBI database using Entrez (NCBI 2004). The steps in homology search and secondary structure prediction used for miRNA identification in this study are shown in Figure 1. Homologous EST and known mature miRNA sequences of three species in the miRBase database were found using BLAST. Each EST sequence was aligned individually against known Rattus norvegicus, Mus musculus, and Homo sapiens miRNA and only those ESTs with a maximum of four mismatches with the query sequence were retained for further analysis. The secondary structures of the resulting mature miRNAs were then predicted using the web-based software mFold 3.2 (Zuker et al. 1999; Zuker 2003). This program is available at http://frontend.bioinfo.rpi.edu/applications/mfold/cgibin/ rnaform1.cgi.

A candidate miRNA sequence was considered if it met the following criteria: (1) the predicted mature miRNA had no more than four nucleotide substitutions when aligned with known *H. sapiens, M. musculus,* and *R. norvegicus* mature miRNAs; (2) the RNA sequence can fold into an appropriate stem-loop hairpin secondary structure; (3) a mature miRNA sequence site is present in one arm of the hairpin structure; (4) there is no loop or break in the miRNA\* sequence; and (5) the predicted secondary structure has a negative minimum free folding energy (MFE;  $\Delta$ G kcal/mol) and 30–70% Adenine+Uracil content (Zhang et al. 2006). These criteria reduced false positives and required that the predicted miRNAs fit the criteria proposed by Ambros and co-workers (2003).

ESTs were used as the basis of the miRNA search because they provide a robust sequence resource that can be exploited for gene discovery, genome annotation, and comparative genomics (Rudd 2003). The use of ESTs gave way for an indirect yet reliable analysis of gene expression in rats which underwent physical exercise. ESTs have also been utilized in similar studies by other researchers, such as Zhang et al. (2005) and Li et al. (2006), in discovering new precursor and mature miRNAs.




Figure 1. A schematic diagram of the over-all procedure used to identify and analyze miRNAs.

\*modified from Lai et al. (2003) and Zhang et al (2006). See text for details.

In this study, an EST sequence was scanned against known miRNA sequences in the miRBase Database using BLAST. Resulting scores and E-values aided in determining which alignment results were significant. Matches with the highest scores were selected as long as the E-values did not exceed the threshold of 10.

Aside from considering rat miRNA alignment results, EST alignments with mouse miRNAs were also selected because the two organisms are very closely related, and miRNAs that are expressed in one of the organisms could be evolutionarily conserved in the other organism as well. Human miRNAs were also included as part of the search, to explore whether rat miRNAs are conserved within the human genome. This way, inferences can be made as to how the potential novel miRNAs will affect different organisms as a result of a specific physical exercise regimen.

Secondary structure prediction served to filter the candidate miRNAs from the previous step by eliminating near-positive outputs. Even if other short RNA sequences can exhibit miRNA functions, only miRNAs can form stem-loop precursors. This process also removed resulting miRNA matches from the BLAST search that were due to chance sequence similarities. The structures deemed qualified for the succeeding steps were those which fully satisfied the criteria proposed by Zhang et al. (2006) and Lai et al. (2003).

### **Potential miRNA Target Prediction**

Using known miRNA sequences as input, the resulting putative miRNAs were tested against the miRBase Target database (miRBase Targets 2006) for brain-specific gene targets. This particular step served to provide information on potential targets of the putative miRNAs since sequence similarity with known miRNAs exists.

The MiRanda algorithm was used for target prediction. This computational method is high-throughput but has the problem of having too many false positives. Targets genes are predicted on the basis of three properties: sequence complementarity, free energy of RNA-RNA duplexes, and conservation of target sites in related genomes. Most likely, not all of the predicted targets for a miRNA represent true biological targets. In fact, only a few of these have been confirmed as either positive or negative. As accurate target prediction and validation are still major obstacles in miRNA research (Zhang et al. 2007), we undertook a systems approach in narrowing down the miRNA targets.

In principle, since miRNAs have evolved to simultaneously regulate their targets by partial complementation, it is likely that the biological effect is carried out through an *en bloc* machinery. That is, the gene targets that have the highest probabilities of being the miRNA target would likely belong to a network having a consistent biological function. Thus, a gene network analysis was carried out using the IPA knowledge database and network construction tools. Aside from determining targets of the putative miRNA, the specific proteins that the target genes code, were identified by searching the UniProt Knowledge Base (UniProtKB) (UniProt 2002).

#### Gene Network (Interactome) Analysis

Pathway models were generated using IPA (Ingenuity Pathways Analysis) Ingenuity<sup>®</sup> Systems, a web-based software application that allows researchers to find interactions between genes and proteins, related networks, functions and diseases, canonical pathways, as well as drug targets and biomarkers (Ingenuity Systems 2006). Focus genes inputted by the user form the "hub" of the networks, allowing for specific interactions to be drawn. Other than meeting the user-set parameters, focus genes must also interact with at least one other gene in the Ingenuity Pathways Knowledge Base (IPKB). When these criteria are met, densely connected networks are drawn (Ingenuity Systems 2006).

The list of genes targeted by the putative miRNAs was imported into the software and the data were analyzed. Networks generated by this program are scored based on the number of Network Eligible molecules they contain, that is, the algorithm maximizes the specific connectivity of each input molecule with the other input molecules. A higher score means a lower probability of finding the observed 'Network Eligible' molecules in a network by chance. As not all 'Network Eligible' molecules may interact directly, other molecules in the IPKB are added to the network, in effect merging smaller networks into a larger one (Ingenuity Systems 2006).

# RESULTS

#### **Identified Novel Putative MicroRNAs**

From the 1199 ESTs identified as changed in the hippocampus following exercise (manuscript in preparation), 3 novel pututative miRNAs from 2 ESTs were identified that could potentially be expressed in

the brain as a result of treadmill running (Table 1). No previously identified miRNAs were arbitrarily represented in any of the exercise-regulated ESTs. The novel miRNAs, all of which are 23 nucleotides long, were assigned as miRNA X, Y, and Z. MiRNA X has its sequence derived from the set of up-regulated genes while the other two (Y and Z) were derived from the list of down-regulated genes. Table 1 also shows the alignment of the three novel putative miRNAs to known miRNAs after searching the miRBase database. MiRNA X is closely matched to miRNA 574-5p of the mouse while miRNA Y and Z are closely related to miRNA-297 of the rat. All three putative miRNAs meet the criteria modified from Zhang et al. (2006).

Figure 2 shows the hairpin loop structures of the potential novel miRNAs generated by mFold. The mature miRNA sequences (in red) of X and Y are both located on the 5' arm of the hairpin loop while miRNA Z has its mature sequence on the 3' arm.

#### Predicted miRNA Targets

Target prediction analysis using the MiRanda algorithm identified 1,878 potential target genes for the 3 novel miRNAs identified. Since miRNA Y and Z are both derived from the same EST and are closely related to the same known miRNA, they have similar targets. The gene targets were filtered using UniProtKB to identify brain-specific genes, narrowing the target gene list to 89. Of these 89 brain-specific genes, 53 are targets of miRNA X and 36 are targets of miRNA Y and Z (Table 2).

#### **IPA-generated Gene Networks (Interactomes)**


The most significant network revealed by the analysis of miRNA X target genes is shown in Fig. 3A. This gene network has an IPA score of 34 and includes 13 of the 53 putative miRNA X targets as nodes (Table 2). The 13 gene targets have functions related to development (disabled homolog 1, homeobox protein Hox-A1, neurophilin-2), molecular transport (ATP-sensitive inward rectifier potassium channel 10, glutamate receptor 2, anion exchange protein

Table 1. Alignment of novel putative miRNAs with known miRNAs, and their thermo-	dynamic properties.

miRNA	EST source	Aligned Candidate miRNA Sequence (top) against a known miRNA Sequence (bottom). Regions of mismatch are in red.	MFE (ΔG kcal/mol)	%A+U content
Х	AI179443	UG <mark>U</mark> GUGUGUGUGUGUGUGUGUGUGUGU (miRNA X) UGAGUGUGUGUGUGUGAGUGUGU(mmu-miR-574-5p)	-29.8	50.55
Y	BE105961	AUGUGUGUGUACAUGUAUGCAUG (miRNA Y) AUGUAUGUGUGCAUGUAUGCAUG (mo-miR-297)	-30.9	62.64
Ζ	BE105961	AUGUAUGUAUGUGUGUAUGUAUG (miRNA Z) AUGUAUGUGUGCAUGUAUGCAUG (mo-miR-297)	-27.6	67.03




Similar to mmu-miR-574-5p



#### miRNA Y

Similar to rno-miR-297








Figure 2. Hairpin secondary structures predicted by mFold 3.2 of the novel putative miRNAs with the mature miRNA sequences in red.

3), activation (GTPase-activating RapGAP domainlike 1, neurogenic locus notch homolog protein 2), receptor-mediated signaling (orexin receptor type 1, zinc finger protein 57), and protein binding (disks large homolog 4, synaptotagmin-3, tripartite motifcontaining protein 3). On the other hand, the most significant network (Fig. 3B) generated by IPA with a score of 23 contained 11 of the 36 potential target genes of miRNA Y and Z (Table 2). Similar to the previous network, the 11 targets have functions related to development (noggin), cellular growth (neurotrophin-3), molecular transport (gamma-aminobutyric acid receptor subunit beta-3, inositol 1,4,5-trisphosphate receptor type 1), catalysis

Table 2. Potential targets of the three novel putative miRNAs expressed in the hippocampus. Target genes of miRNA X are down-regula	ated
while those of miRNA Y and Z are up-regulated.	

MiRNA	Targeted Genes	Target Function	Remarks
Č.	Garnl1*	Activator	GTPase-activating RapGAP domain-like 1
	Notch2*	Activator, Developmental protein, Receptor	Neurogenic locus notch homolog protein 2 [Precursor]
	Pcp4	Brain-specific polypeptide	Brain-specific polypeptide PEP-19
	Clic4	Channel	Chloride intracellular channel protein 4
	Kenh5	Channel	Potassium voltage-gated channel subfamily H member 5
	Kcnj10*	Channel	ATP-sensitive inward rectifier potassium channel 10
	Trpv1	Channel	Transient receptor potential cation channel subfamily V member 1
	Gria2*	Channel, Receptor	Glutamate receptor 2 [Precursor]
	Dab1*	Developmental protein	Disabled homolog 1
	Hoxa1*	Developmental protein	Homeobox protein Hox-A1
	Pdlim7	Developmental protein	PDZ & LIM domain protein 7
	Sncg	Developmental protein	Gamma-synuclein
	Pak3	Developmental protein, Enzyme	Serine/threonine-protein kinase PAK 3
	Ntrk1	Developmental protein, Enzyme, Receptor	High affinity nerve growth factor receptor [Precursor]
	Nrp2*	Developmental protein, Receptor, Enzyme	Neurophilin-2 [Precursor]
	B4GALNT4	Enzyme	N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosa minyl transferase 1
	Enpp5	Enzyme	Ectonucleotide pyrophos-phatase / phosphodiesterase family member 5 [Precursor]
	Hmox2	Enzyme	Heme oxygenase 2
	Pnpla7	Enzyme	Patatin-like phospholipase domain-containing protein 7
	Senp2	Enzyme	Sentrin-specific protease 2
	Tnk2	Enzyme	Activated CDC42 kinase 1
	Acvr1b	Enzyme, Receptor	Activin receptor type-1B [Precursor]
	Fgf14	Growth factor	Fibroblast growth factor 14
	Ngfb	Growth factor	Beta-nerve growth factor [Precursor]
	Cort	Hormone	Cortistatin [Precursor]
	Rln3	Hormone	Relaxin-3 [Ptrecursor]
	Nppc	Hormone, Vasoactive	C-type natriuretic peptide [Precursor]
	Phactr3	Inhibitor	Phosphatase & actin regulator 3
	Rgs9	Inhibitor	Regulator of G-protein signaling 9
	Qrfp	Neuropeptide	Orexigenic neuropeptide QRFP [Precursor]
	Atxn10	Protein binding	Ataxin-10
	Bzrap1	Protein binding	Peripheral-type benzodiazepine receptor-associated protein 1
	Crip2	Protein binding	Cysteine-rich protein 2
	Dlg4*	Protein binding	Disks large homolog 4
	Elavl4	Protein binding	ELAV-like protein 4
	Ncam1	Protein binding	Neural cell adhesion molecule 1, 140 kDa isoform [Precursor]
	Syt3*	Protein binding	Synaptotagmin-3
	Trim3*	Protein binding	Tripartite motif-containing protein 3
	Nr4a1	Receptor	Nuclear receptor subfamily 4 group A member 1
	Cry2	Receptor, Repressor	Cryptochrome-2
	Mrgprb4	Receptor, Transducer	Mas-related G-protein coupled receptor member B4
	Oprm1	Receptor, Transducer	Mu-type opioid receptor
	Adrala	Receptor, Transducer	Alpha-1A adrenergic receptor
	Drd5	Receptor, Transducer	D(1B) dopamine receptor
	Gpr30	Receptor, Transducer	Membrane estrogen receptor
	Slc18a3	•	
	5101085	Transporter	Vesicular acetylcholine transporter


	Slc4a3*	Transporter	Anion exchange protein 3
	Syngr1	Transporter	Synaptogyrin-1
	Iiig9	Unspecified	Uncharacterized protein C11orf66 homolog
Y and Z	Clic6	Channel	Chloride intracellular channel 6
	Gabrb3*	Channel	Gamma-aminobutyric acid receptor subunit beta-3 [Precursor]
	Kenv1	Channel	Potassium voltage-gated channel subfamily V member 1
	Syt17	Channel	Synaptotagmin-17
	Itpr1*	Channel, Receptor	Inositol 1,4,5-trisphosphate receptor type 1
	Bag5	Chaperone	BAG family molecular chaperone regulator 5
	Nog*	Developmental protein	Noggin [Precursor] [Fragment]
	Acly*	Enzyme	ATP-citrate synthase
	Cacnalg	Enzyme	Voltage-dependent T-type calcium channel subunit alpha-1G
	Enpp5	Enzyme	Ectonucleotide pyrophos-phatase/phosphodiesterase family membe 5 [Precursor]
	Mast1	Enzyme	Microtubule-associated serine/threonine-protein kinase 1
	Pde4b	Enzyme	cAMP-specific 3',5'-cyclic phosphodiesterase 4B
	Pla2g4a*	Enzyme	Cytosolic phospholipase A2
	Pnck	Enzyme	Calcium/calmodulin-dependent protein kinase type 1B
	Ppm1e	Enzyme	Protein phosphatase 1E
	Ppp2r2d	Enzyme	Serine/threonine-protein phosphatase 2A 55 kDa regulatory subun B delta isoform
	Scp2	Enzyme	Non-specific lipid-transfer protein
	Epha6	Enzyme, Receptor	Ephrin type-A receptor 6 [Precursor]
	Epha8	Enzyme, Receptor	Ephrin type-A receptor 8
	Ntf3*	Growth factor	Neurotrophin-3 [Precursor]
	App*	Inhibitor	Amyloid beta A4 protein [Precursor]
	Znf354c*	Inhibitor, Repressor	Zinc finger protein 354C
	Fgfbp1	Protein binding	Fibroblast growth factor-binding protein 1 [Precursor]
	Kiss1*	Protein binding	Metastasis-suppressor KiSS-1 [Precursor]
	Pard3	Protein binding	Partitioning-defective 3 homolog
	Raver1	Protein binding	Ribonucleoprotein PTB-binding 1
	Sep15	Protein binding	15 kDa selenoprotein
	Sfrs12	Protein binding	Splicing factor, arginine/serine-rich 12
	Nr4a1*	Receptor	Nuclear receptor subfamily 4 group A member 1
	Cntn3	Receptor	Contactin-3
	Oprs1	Receptor	Sigma 1-type opioid receptor
	Sv2a	Receptor	Synaptic vesicle glycoprotein 2A
	Eltd1	Receptor, Transducer	EGF, latrophilin and seven transmembrane domain-containing protein 1 [Precursor]
	Oprm1*	Receptor, Transducer	Mu-type opioid receptor
	Prokr2	Receptor, Transducer	Prokineticin receptor 2
	Kalrn	Releasing factor, Enzyme	Kalirin


\*node in resulting IPA network

(ATP-citrate synthase, cytosolic phospholipase A2), inhibition (amyloid beta A4 protein, zinc finger protein 354C), receptor-mediated signaling (nuclear receptor subfamily 4 group A member 1, mu-type opioid receptor) and protein binding (metastasissuppressor KiSS-1).

# DISCUSSION

Utilizing bioinformatics tools and databases, we identified three putative miRNAs expressed in the rat brain during treadmill running that target several proteins, some of which are related to brain activities. One miRNA found on the EST AI179443 is similar to mmu-miR-574-5p (miRNA X) while two of the novel putative miRNAs were found on the EST BE105961 (termed miRNA Y and Z).





indirect interaction

Figure 3. The most significant network of genes targeted by (A) miRNAX and (B) miRNA Y/Z that are expressed in the rat brain during treadmill running. The nodes and the nature of gene interactions are indicated in the Legend.

Function	-log (p-value)	Molecules
Behavior	6.67x10 <sup>-7</sup> - 2.2 x10 <sup>-2</sup>	NGFB, OPRM1, DLG4, CRY2, QRFP, DRD5, ADRA1A, CORT, RGS9, HCRTR1, GRIA2, TRPV1, NTRK1
Nervous System Development and Function	7.46x10 <sup>-7</sup> - 2.2 x10 <sup>-2</sup>	NCAM1, NGFB, TRIM3, HMOX2, OPRM1, NRP2, NPPC, ELAVL4, DLG4, CRY2, KCNJ10, FGF14, ZFP57, DRD5, CORT, DAB1, HOXA1, HCRTR1, GRIA2, TRPV1, SYNGR1, NTRK1, PCP4
Neurological Disease	1.27 x10 <sup>-6</sup> - 2.2 x10 <sup>-2</sup>	NCAM1, NGFB, OPRM1, HMOX2, ELAVL4, DLG4, KCNJ10, FGF14, DRD5, ADRA1A, DAB1, RGS9, PAK3, ATXN10, GRIA2, TRPV1, PCP4, NTRK1
Organismal Injury and Abnormalities	1.27 x10 <sup>-6</sup> - 2.2 x10 <sup>-2</sup>	NGFB, NRP2, DRD5, OPRM1, ADRA1A, GRIA2, TRPV1
Gastrointestinal Disease	1.02 x10 <sup>-5</sup> - 9.58 x10 <sup>-3</sup>	DRD5, OPRM1, CORT, TRPV1
Inflammatory Disease	1.02 x10 <sup>-5</sup> - 1.73 x10 <sup>-2</sup>	NGFB, OPRM1, CORT, KCNJ10, TRPV1, NR4A1
Cancer	1.34 x10 <sup>-5</sup> - 2.33 x10 <sup>-2</sup>	NCAM1, NGFB, ADRA1A, HOXA1, SNCG, PAK3, NOTCH2, TNK2, NR4A1, NTRK1
Cell-To-Cell Signaling and Interaction	$1.34 \text{ x}10^{-5} - 2.2 \text{ x}10^{-2}$	NCAM1, NGFB, NRP2, DRD5, CORT, DLG4, HCRTR1, GRIA2, NTRK1
Cellular Function and Maintenance	1.34 x10 <sup>-5</sup> - 1.47 x10 <sup>-2</sup>	NCAM1, NGFB, NOTCH2, NTRK1
Skeletal and Muscular Disorders	1.34 x10 <sup>-5</sup> - 7.4 x10 <sup>-3</sup>	NGFB, NPPC, NTRK1
Cell Morphology	4.02 x10 <sup>-5</sup> - 2.2 x10 <sup>-2</sup>	NCAM1, NGFB, NRP2, SNCG, NPPC, DLG4, ELAVL4, KCNJ10, TNK2, DRD5, HOXA1, PAK3, CLIC4, GRIA2, SYNGR1, NTRK1, NR4A1
Tissue Development	$4.02 \text{ x}10^{-5} - 2.3 \text{ x}10^{-2}$	NCAM1, NGFB, NRP2, NPPC, HOXA1, DAB1, TRPV1, ACVR1B, NTRK1
Psychological Disorders	5.05 x10 <sup>-5</sup> - 2.2 x10 <sup>-2</sup>	OPRM1, DRD5, ADRA1A, ELAVL4, DLG4, PCP4
Cell Cycle	8.02 x10 <sup>-5</sup> - 2.23 x10 <sup>-2</sup>	NGFB, ADRA1A, NOTCH2, NR4A1
Endocrine System Disorders	8.02 x10 <sup>-5</sup> - 2.2 x10 <sup>-2</sup>	NCAM1, NGFB, ADRA1A, PAK3, NTRK1
Lipid Metabolism	8.02 x10 <sup>-5</sup> - 1.84 x10 <sup>-2</sup>	QRFP, NGFB, ADRA1A, NPPC, NTRK1
Small Molecule Biochemistry	8.02 x10 <sup>-5</sup> - 1.84 x10 <sup>-2</sup>	NGFB, SLC18A3, HMOX2, OPRM1, NPPC, DLG4, QRFP, DRD5, ADRA1A, RGS9, GRIA2, NTRK1, RLN3
Cellular Development	1.16 x10 <sup>-4</sup> - 2.2 x10 <sup>-2</sup>	NCAM1, NGFB, NRP2, NPPC, NOTCH2, PDLIM7, KCNJ10, TNK2, CRIP2, HOXA1, ADRA1A, PAK3, CLIC4, ACVR1B, NR4A1, NTRK1
Cell Signaling	1.65 x10 <sup>-4</sup> - 1.95 x10 <sup>-2</sup>	NCAM1, NGFB, OPRM1, NPPC, DLG4, NOTCH2, TNK2, QRFP, DRD5, CORT, ADRA1A, DAB1, RGS9, PAK3, HCRTR1, GPER, GRIA2, TRPV1, RLN3, NTRK1
Molecular Transport	1.65 x10 <sup>-4</sup> - 1.95 x10 <sup>-2</sup>	NCAM1, NGFB, SLC18A3, OPRM1, NPPC, DLG4, KCNJ10, QRFP, DRD5, ADRA1A, CORT, GRIA2, TRPV1, RLN3
Nucleic Acid Metabolism	1.65 x10 <sup>-4</sup> - 1.84 x10 <sup>-2</sup>	OPRM1, DRD5, ADRA1A, NPPC, RGS9, DLG4, RLN3
Genetic Disorder	4.76 x10 <sup>-4</sup> - 7.4 x10 <sup>-3</sup>	OPRM1, DRD5, RGS9, ATXN10
Cell Death	1.02 x10 <sup>-3</sup> - 2.2 x10 <sup>-2</sup>	NGFB, OPRM1, HMOX2, NPPC, TRPV1, NR4A1,NTRK1
Cellular Assembly and Organization	1.19 x10 <sup>-3</sup> - 1.84 x10 <sup>-2</sup>	NCAM1, NGFB, NRP2, HOXA1, DAB1, DLG4, RGS9, ELAVL4, GRIA2, SYNGR1, NTRK1
Cellular Movement	1.19 x10 <sup>-3</sup> - 2.2 x10 <sup>-2</sup>	NCAM1, NGFB, DRD5, OPRM1, NRP2, SNCG, DAB1, HOXA1, NPPC, CLIC4, GRIA2, TRPV1
Immunological Disease	1.56 x10 <sup>-3</sup> - 2.2 x10 <sup>-2</sup>	NGFB, OPRM1
Cardiovascular System Development and Function	$1.62 \text{ x}10^{-3} - 2.2 \text{ x}10^{-2}$	QRFP, DRD5, NRP2, ADRA1A, NPPC, TRPV1
Cellular Growth and Proliferation	2.41 x10 <sup>-3</sup> - 2.27 x10 <sup>-2</sup>	NCAM1, NGFB, NRP2, OPRM1, SNCG, NPPC, NOTCH2, CRIP2, CORT, HOXA1, ADRA1A, GPER, NTRK1, NR4A1

### Table 3. The top biological functions (generated using IPA Core Analysis) of miRNA X targets.

Reproductive System Disease	2.41 x10 <sup>-3</sup> - 1.11 x10 <sup>-2</sup>	NGFB, HOXA1, SNCG, NR4A1, NTRK1
Digestive System Development and Function	3.32 x10 <sup>-3</sup> - 1.82 x10 <sup>-2</sup>	QRFP, OPRM1, HCRTR1, TRPV1, RLN3
Cardiovascular Disease	3.71 x10 <sup>-3</sup> - 1.99 x10 <sup>-2</sup>	NGFB, OPRM1, DRD5, ADRA1A, GRIA2
Cellular Compromise	3.71 x10 <sup>-3</sup> - 1.11 x10 <sup>-2</sup>	NCAM1, SNCG, KCNJ10, GRIA2
Connective Tissue Development and Function	3.71 x10 <sup>-3</sup> - 2.2 x10 <sup>-2</sup>	NGFB, NPPC, NTRK1
Embryonic Development	3.71 x10 <sup>-3</sup> - 2.3 x10 <sup>-2</sup>	NCAM1, NGFB, NRP2, NPPC, HOXA1, DAB1, SLC2A3, ACVR1B
Endocrine System Development and Function	3.71 x10 <sup>-3</sup> - 2.2 x10 <sup>-2</sup>	NCAM1, QRFP, NGFB
Hair and Skin Development and Function	3.71 x10 <sup>-3</sup> - 1.84 x10 <sup>-2</sup>	NGFB, ADRA1A
Hematological System Development & Function	3.71 x10 <sup>-3</sup> - 1.86 x10 <sup>-2</sup>	NGFB, CORT, NOTCH2, NTRK1, NR4A1
Immune / Lymphatic System Development and Function	3.71 x10 <sup>-3</sup> - 1.86 x10 <sup>-2</sup>	NCAM1, NGFB, CORT, NOTCH2, NTRK1, NR4A1

Table 4. The top biological functions (generated using IPA Core Analysis) of miRNA Y and Z targets.
---

Function	-log(p-value)	Molecules
Lipid Metabolism	2.28 x10 <sup>-6</sup> -1.36 x10 <sup>-2</sup>	SCP2, KISS1, PROKR2, PLA2G4A, NTF3, ACLY, OPRS1, APP
Molecular Transport	2.28 x10 <sup>-6</sup> -1.36 x10 <sup>-2</sup>	SCP2, PROKR2, KISS1, OPRM1, PLA2G4A, NTF3, OPRS1, ITPR1, APP
Small Molecule Biochemistry	2.28 x10 <sup>-6</sup> -1.36 x10 <sup>-2</sup>	SCP2, KISS1, PROKR2, PLA2G4A, NTF3, SV2A, ACLY, OPRS1, APP
Organismal Injury and Abnormalities	1.54 x10 <sup>-5</sup> -1.36 x10 <sup>-2</sup>	OPRM1, PLA2G4A, GABRB3, PDE4B, NOG, OPRS1, CACNA1G, APP
Cardiovascular Disease	2.98 x10 <sup>-5</sup> -1.36 x10 <sup>-2</sup>	OPRM1, PLA2G4A, PDE4B, OPRS1, CACNA1G, APP
Neurological Disease	2.98 x10 <sup>-5</sup> -1.36 x10 <sup>-2</sup>	PARD3, OPRM1, GABRB3, NTF3, PDE4B, SV2A, OPRS1, BAG5, APP
Nervous System Development and Function	4.31 x10 <sup>-5</sup> -1.48 x10 <sup>-2</sup>	PARD3, EPHA8, GABRB3, KALRN, NTF3, SV2A, OPRS1, NOG, CNTN3, ITPR1, APP
Cellular Function/Maintenance	4.96 x10 <sup>-5</sup> -1.36 x10 <sup>-2</sup>	NTF3, ITPR1, APP
Hematological Disease	4.96 x10 <sup>-5</sup> -1.19 x10 <sup>-2</sup>	SCP2, OPRM1, PLA2G4A, PDE4B, OPRS1, APP, NR4A1
Renal and Urological Disease	4.96 x10 <sup>-5</sup> -4.96 x10 <sup>-5</sup>	OPRM1, OPRS1
Tissue Morphology	7.43 x10 <sup>-5</sup> -1.36 x10 <sup>-2</sup>	NTF3, NOG, APP
Psychological Disorders	1.38 x10 <sup>-4</sup> -6.98 x10 <sup>-4</sup>	OPRM1, GABRB3, OPRS1, APP
Genetic Disorder	1.78 x10 <sup>-4</sup> -1.13 x10 <sup>-2</sup>	OPRM1, OPRS1, NOG, APP
Cell Morphology	2.22 x10 <sup>-4</sup> -1.36 x10 <sup>-2</sup>	SCP2, PLA2G4A, KALRN, NTF3, NOG, APP
Cellular Assembly and Organization	2.22 x10 <sup>-4</sup> -1.44 x10 <sup>-2</sup>	SCP2, PARD3, EPHA8, KALRN, NTF3, ITPR1, APP
Cell-To-Cell Signaling and Interaction	2.71 x10 <sup>-4</sup> -1.45 x10 <sup>-2</sup>	EPHA8, NTF3, SV2A, CNTN3, APP
Skeletal and Muscular System Development and Function	2.71 x10 <sup>-4</sup> -1.36 x10 <sup>-2</sup>	PLA2G4A, GABRB3, NOG, CACNA1G, APP
Cell Death	4.46 x10 <sup>-4</sup> -1.36 x10 <sup>-2</sup>	OPRM1, PLA2G4A, NTF3, ITPR1, APP, NR4A1
Cellular Movement	1.25 x10 <sup>-3</sup> -1.42 x10 <sup>-2</sup>	KISS1, OPRM1, EPHA8, PLA2G4A, NTF3, PDE4B, NOG, APP
Behavior	1.33 x10 <sup>-3</sup> -1.48 x10 <sup>-2</sup>	OPRM1, GABRB3, NTF3, OPRS1, APP
Auditory and Vestibular System Development and Function	2.28 x10 <sup>-3</sup> -6.81 x10 <sup>-3</sup>	NTF3
Cancer	2.28 x10 <sup>-3</sup> -1.23 x10 <sup>-2</sup>	KISS1, PLA2G4A, KALRN, NTF3, FGFBP1, NOG, CACNA1G, APP NR4A1
Cell Signaling	2.28 x10 <sup>-3</sup> -1.13 x10 <sup>-2</sup>	KISS1, PROKR2, OPRM1, NTF3, OPRS1, ITPR1, APP
Cellular Compromise	2.28 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	PPM1E, NTF3, BAG5, APP

Philippine Journal of Science Vol. 139 No. 1, June 2010

Cellular Covuti and Proliferation     228 $x10^3.1.36 x10^2$ NTF3, NOG, APP       Cellular Growth and Proliferation     228 $x10^3.1.36 x10^2$ KISSI, PLA2GAA, NTF3, FGFBP1, NOG, CACNAIG, NR4A1       Connective Tissue Development and Function     228 $x10^3.1.36 x10^2$ NOG, APP       Developmental Disorder     228 $x10^3.1.36 x10^2$ NOG, APP       Developmental Disorder     228 $x10^3.1.36 x10^2$ PLA2GAA, NOG, APP       Drug Metabolism     228 $x10^3.2.28 x10^2$ SV2A, OPRS1       Gastrointestinal Disease     228 $x10^3.1.25 x10^2$ OPRM1, PLA2GAA, NOG, APP       Inflammatory Disease     228 $x10^3.1.25 x10^2$ OPRM1, PLA2GAA, PDE4B, APP, NR4A1       Metabolis     228 $x10^3.1.25 x10^2$ OPRM1, PLA2GAA, DPL4B, APP, NR4A1       Metabolis Disease     228 $x10^3.1.3 x10^2$ OPRM1, PLA2GAA, NOG, APP       Vitamin and Mineral Metabolism     228 $x10^3.1.3 x10^2$ SCP2       Cell Cycle     455 $x10^3.1.36 x10^2$ SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APP       Gene Expression     455 $x10^3.1.36 x10^2$ SCP2, KISS1, PROKR2, ORGM1, NTF3, ACLY, OPRS1, ITPR1, APP       Gene Expression     455 $x10^3.1.36 x10^2$ OPRM1, PLA2G4A, ZPR5454C, NOG, APP       Gene Expressio			
Connective Tissue Development and Function $2.28 \times 10^3.1.36 \times 10^2$ NOG, APPConnective Tissue Disorders $2.28 \times 10^3.1.36 \times 10^2$ NOG, APPDigestive System Development and Function $2.28 \times 10^3.2.28 \times 10^2$ APPDigestive System Development and Function $2.28 \times 10^3.2.28 \times 10^2$ SV2A, OPRS1Gastrointestinal Disease $2.28 \times 10^3.2.28 \times 10^2$ OPRM1, PLA2G4A, PDE4B, APPInflammatory Disease $2.28 \times 10^3.2.28 \times 10^3$ OPRM1, PLA2G4A, PDE4B, APP, NR4A1Metabolisin $2.28 \times 10^3.2.28 \times 10^3$ SCP2Nucleic Acid Metabolism $2.28 \times 10^3.1.25 \times 10^2$ OPRM1, PLA2G4A, PDE4B, APP, NR4A1Metabolic Disease $2.28 \times 10^3.1.25 \times 10^2$ SCP2, ACLYNucleic Acid Metabolism $2.28 \times 10^3.1.3 \times 10^2$ SCP2, ACLYVitamin and Mineral Metabolism $2.28 \times 10^3.1.3 \times 10^2$ SCP2, ACLYVitamin and Mineral Metabolism $2.28 \times 10^3.1.3 \times 10^2$ SCP2, ACLYCell Cycle $4.55 \times 10^3.1.36 \times 10^2$ NNGA, APPCell Cycle $4.55 \times 10^3.1.36 \times 10^2$ NNGA, PPCell Cycle $4.55 \times 10^3.1.36 \times 10^2$ NNGA, PPImmune Response $4.55 \times 10^3.1.36 \times 10^2$ NOG, APPOrgan Development $6.81 \times 10^3.907 \times 10^3$ NTE3, NOG, APPInfarmation $6.81 \times 10^3.907 \times 10^3$ NOGViral Infection $6.81 \times 10^3.2.37 \times 10^3$ NOGViral Infection $6.81 \times 10^3.2.37 \times 10^3$ NOGPhereopment and Function $6.81 \times 10^3.2.37 \times 10^3$ NOGRenal and Urological System $6.81 \times 10^3.2.37 \times 10^3$	Cellular Development	2.28 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	NTF3, NOG, APP
Function $228 \times 10^{-1}.13 \times 10^{-1}$ NOG, APP       Connective Tissue Disorders $228 \times 10^{-1}.13 \times 10^{-2}$ NOG, APP       Developmental Disorder $228 \times 10^{-1}.13 \times 10^{-2}$ PLA2G4A, NOG, APP       Digestive System Development and Function $228 \times 10^{-2}.228 \times 10^{-2}$ APP       Organ Metabolism $228 \times 10^{-2}.228 \times 10^{-2}$ SV2A, OPRS1       Gastrointestinal Disease $228 \times 10^{-3}.11 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APP       Inflammatory Disease $228 \times 10^{-3}.11 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APP, NR4A1       Metabolic Disease $228 \times 10^{-3}.11 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APP, NR4A1       Metabolic Disease $228 \times 10^{-3}.11 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APP, NR4A1       Nucleic Acid Metabolism $228 \times 10^{-3}.13 \times 10^{-2}$ SCP2, ACLY       Vitamin and Mineral Metabolism $228 \times 10^{-3}.13 \times 10^{-2}$ SCP2, ACLY       Vitamin and Mineral Metabolism $228 \times 10^{-3}.13 \times 10^{-2}$ SCP2, ACLY       Vitamin and Mineral Metabolism $228 \times 10^{-3}.13 \times 10^{-2}$ NOG, APP       Cardicosecular System Development $455 \times 10^{-3}.13 \times 10^{-2}$ NOG, APP       Immune Response $455 \times 10^{-3}.13$	Cellular Growth and Proliferation	2.28 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	KISS1, PLA2G4A, NTF3, FGFBP1, NOG, CACNA1G, NR4A1
I evelopmental Disorder28 x 10 <sup>3</sup> -1.36 x 10 <sup>2</sup> PLA2G4A, NOG, APPDiggstice System Development and Function2.28 x 10 <sup>-1</sup> -2.28 x 10 <sup>2</sup> APPOrag Metabolism2.28 x 10 <sup>-1</sup> -2.28 x 10 <sup>2</sup> SVZA, OPRS1Gastroinestinal Disease2.28 x 10 <sup>-1</sup> -1.13 x 10 <sup>2</sup> OPRMI, PLA2G4A, DDE4B, APPInflammatory Disease2.28 x 10 <sup>-1</sup> -1.25 x 10 <sup>2</sup> OPRMI, PLA2G4A, PDE4B, APP, NR4A1Metabolis Disease2.28 x 10 <sup>-1</sup> -1.25 x 10 <sup>2</sup> SCP2, ACLYNucleic Acid Metabolism2.28 x 10 <sup>-1</sup> -1.13 x 10 <sup>2</sup> SCP2, X ISS1, PROKR2, OPRMI, NTF3, ACLY, OPRS1, ITPR1, APPYiamin and Mineral Metabolism2.28 x 10 <sup>-1</sup> -1.13 x 10 <sup>2</sup> SCP2, X ISS1, PROKR2, OPRMI, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development4.55 x 10 <sup>-1</sup> -1.36 x 10 <sup>2</sup> NGG, APPGene Expression4.55 x 10 <sup>-1</sup> -1.36 x 10 <sup>2</sup> NGG, APPImmune Response4.55 x 10 <sup>-1</sup> -1.36 x 10 <sup>2</sup> NGG, APPImmune Response4.55 x 10 <sup>-1</sup> -1.36 x 10 <sup>2</sup> NFI, NLA2G4A, ZNF354C, NOG, APPInflametion4.55 x 10 <sup>-1</sup> -1.36 x 10 <sup>2</sup> NGG, APPInflametion4.55 x 10 <sup>-1</sup> -1.36 x 10 <sup>2</sup> NFI, NLA2G4A, ZNF354C, NOG, APPInflametion6.35 x 10 <sup>-1</sup> -3.05 x 10 <sup>-1</sup> NFI, NLA2G4A, ZNF354C, NOG, APPInflametion6.35 x 10 <sup>-1</sup> -3.05 x 10 <sup>-1</sup> NFI, NGA, APPInflametion6.35 x 10 <sup>-3</sup> -0.71 x 10 <sup>-1</sup> NFI, NG, APPInflametion6.35 x 10 <sup>-3</sup> -0.71 x 10 <sup>-1</sup> NFIInflametion6.31 x 10 <sup>-3</sup> -0.71 x 10 <sup>-1</sup> NFIInflametion6.31 x 10 <sup>-3</sup> -0.71 x 10 <sup>-1</sup> NFIInflametion6.31 x 10 <sup>-3</sup> -0.71 x 10 <sup>-1</sup> <td></td> <td>2.28 x10<sup>-3</sup>-1.36 x10<sup>-2</sup></td> <td>NOG, APP</td>		2.28 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	NOG, APP
Digestive System Development and Function $2.28 \times 10^{-2} 2.28 \times 10^{-2}$ APPDrug Metabolism $2.28 \times 10^{-1} 2.28 \times 10^{-2}$ SV2A, OPRS1Gastrointestinal Disease $2.28 \times 10^{-1} .13 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APPInflammatory Disease $2.28 \times 10^{-1} .12 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APP, NR4A1Metabolic Disease $2.28 \times 10^{-1} .12 \times 10^{-2}$ SCP2Nucleic Acid Metabolism $2.28 \times 10^{-1} .13 \times 10^{-2}$ SCP2, XLS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development and Function $4.55 \times 10^{-1} .13 \times 10^{-2}$ SCP2, XLS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development and Function $4.55 \times 10^{-1} .13 \times 10^{-2}$ SCP2, XLS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development and Function $4.55 \times 10^{-1} .13 \times 10^{-2}$ PARD3, PLA2G4A, NOG, APPGene Expression $4.55 \times 10^{-1} .13 \times 10^{-2}$ PNR4A1Embryonic Development and Function $4.55 \times 10^{-1} .13 \times 10^{-2}$ PORM1, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^{-1} .13 \times 10^{-2}$ PARD3, PLA2G4A, ZNF354C, NOG, APPNegroductive System Development and Function $6.81 \times 10^{-3} .07 \times 10^{-3}$ NTF3, NOG, APPPorgan Development and Function $6.81 \times 10^{-3} .907 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} .907 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} .907 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} .907 \times 1$	Connective Tissue Disorders	2.28 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	NOG, APP
Function     2.38 x10 <sup>-2</sup> .28 x10     APP       Drug Metabolism     2.28 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> SV2A, OPRS1       Gastrointestinal Disease     2.28 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> OPRM1, PLA2G4A, PDE4B, APP       Hematological System Development and Function     2.28 x10 <sup>-3</sup> .12 x10 <sup>-2</sup> OPRM1, PLA2G4A, PDE4B, APP, NR4A1       Metabolic Disease     2.28 x10 <sup>-3</sup> .12 x10 <sup>-2</sup> OPRM1, PLA2G4A, PDE4B, APP, NR4A1       Metabolic Disease     2.28 x10 <sup>-3</sup> .12 x10 <sup>-3</sup> SCP2       Nucleic Acid Metabolism     2.28 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> SCP2, XISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APP       Cardiovascular System Development and Function     4.55 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> SCP2, XISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APP       Cell Cycle     4.55 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> SCP2, XISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APP       Cardiovascular System Development and Function     4.55 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> PLA2G4A, NOG, APP       Immune Response     4.55 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> OPRM1, PLA2G4A, ZNF354C, NOG, APP       Immune Response     4.55 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> OPRM1, PLA2G4A, ZNF354C, NOG, APP       Viral Infection     4.55 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> OPRM1, PLA2G4A, ZNF354C, NOG, APP       Immune Response     4.55 x10 <sup>-3</sup> .13 x10 <sup>-2</sup> NOG	Developmental Disorder	2.28 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	PLA2G4A, NOG, APP
Gastrointestinal Disease $2.28 \times 10^3 \cdot 1.13 \times 10^2$ OPRMI, PLA2G4AHematological System Development $2.28 \times 10^3 \cdot 1.41 \times 10^2$ OPRMI, PLA2G4A, PDE4B, APPInflammatory Disease $2.28 \times 10^3 \cdot 1.25 \times 10^2$ OPRMI, PLA2G4A, PDE4B, APP, NR4A1Metabolic Disease $2.28 \times 10^3 \cdot 1.25 \times 10^2$ OPRMI, PLA2G4A, PDE4B, APP, NR4A1Metabolic Disease $2.28 \times 10^3 \cdot 1.13 \times 10^2$ SCP2Nucleic Acid Metabolism $2.28 \times 10^3 \cdot 1.13 \times 10^2$ SCP2, ACLYVitamin and Mineral Metabolism $2.28 \times 10^3 \cdot 1.13 \times 10^2$ SCP2, XLSSI, PROKR2, OPRMI, NTF3, ACLY, OPRSI, ITPR1, APPCardiovascular System Development $4.55 \times 10^3 \cdot 1.36 \times 10^2$ PLA2G4A, NOG, APPCell Cycle $4.55 \times 10^3 \cdot 1.36 \times 10^2$ NOG, APPImmune Response $4.55 \times 10^3 \cdot 1.36 \times 10^2$ NOG, APPImmune Response $4.55 \times 10^3 \cdot 1.36 \times 10^2$ PRM1, PLA2G4A, PDE4B, APPArd Function $4.55 \times 10^3 \cdot 1.36 \times 10^2$ OPRMI, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^3 \cdot 1.36 \times 10^2$ NOG, APPImmune Response $6.81 \times 10^3 \cdot 1.36 \times 10^2$ APPOrgan Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NTF3, NOG, APPIndertion $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGVisual System Development and Function $6.81 \times 10^3 \cdot 1.36 \times 10^2$ OPRM1, PLA2G4A, TPR1, NR4A1Post-Timaslational Modification $9.73 \times 10^3 \cdot 1.75 \times 10^3$ NTG3Immunological Disease $8.74 \times 10^3 \cdot 1.26 \times 10^3$ OPRImmunologistom Disorders $1.13 \times 10^2 \cdot 1.13 \times 10^2$ APPImmunologistom Dis		2.28 x10 <sup>-3</sup> -2.28 x10 <sup>-2</sup>	APP
Henatological System Development2.28 x10 <sup>-3</sup> .1.41 x10 <sup>2</sup> OPRM1, PLA2G4A, PDE4B, APPInflammatory Disease2.28 x10 <sup>-3</sup> .1.25 x10 <sup>2</sup> OPRM1, PLA2G4A, PDE4B, APP, NR4A1Metabolic Disease2.28 x10 <sup>-3</sup> .2.28 x10 <sup>3</sup> SCP2Nucleic Acid Metabolism2.28 x10 <sup>-3</sup> .1.3 x10 <sup>2</sup> SCP2, ACLYVitamin and Mineral Metabolism2.28 x10 <sup>-3</sup> .1.13 x10 <sup>2</sup> SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> PLA2G4A, NOG, APPCell Cycle4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> PNR4A1Embryonic Development4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> PRM3, PLA2G4A, ZNF354C, NOG, APPImmune Response4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> PRM1, PLA2G4A, PDE4B, APPReproductive System Development4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> PRM1, PLA2G4A, ZNF354C, NOG, APPImmune Response4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> PRM1, PLA2G4A, PDE4B, APPViral Infection4.55 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> PRIndercion6.81 x10 <sup>-3</sup> .1.36 x10 <sup>2</sup> APPIndercion6.81 x10 <sup>-3</sup> .9.07 x10 <sup>3</sup> NTG3, NOG, APPIndercion6.81 x10 <sup>-3</sup> .1.35 x10 <sup>3</sup> NGGVisual System Development and Function6.81 x10 <sup>-3</sup> .1.35 x10 <sup>-3</sup> Visual System Development and Function6.81 x10 <sup>-3</sup> .1.35 x10 <sup>-3</sup> Visual System Development and Function6.81 x10 <sup>-3</sup> .1.35 x10 <sup>-3</sup> NGGPrePart Tom Station Development and Function6.81 x10 <sup>-3</sup> .1.35 x10 <sup>-3</sup> Nord <td>Drug Metabolism</td> <td>2.28 x10<sup>-3</sup>-2.28 x10<sup>-2</sup></td> <td>SV2A, OPRS1</td>	Drug Metabolism	2.28 x10 <sup>-3</sup> -2.28 x10 <sup>-2</sup>	SV2A, OPRS1
and Function     2.2 x 10 <sup>-1</sup> .1 x 10 <sup>-1</sup> OPRM1, PLA2GA, PDE4B, APP       Inflammatory Disease     2.2 x 10 <sup>-3</sup> .1.2 x 10 <sup>-3</sup> OPRM1, PLA2G4A, PDE4B, APP, NR4A1       Metabolic Disease     2.2 x 10 <sup>-3</sup> .2.2 x 10 <sup>-3</sup> SCP2       Nucleic Acid Metabolism     2.28 x 10 <sup>-3</sup> .1.1 x 10 <sup>-2</sup> SCP2, ACLY       Vitamin and Mineral Metabolism     2.2 x 10 <sup>-3</sup> .1.1 x 10 <sup>-2</sup> SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APP       Cardiovascular System Development     4.55 x 10 <sup>-3</sup> .1.3 6 x 10 <sup>-2</sup> PLA2G4A, NOG, APP       Cell Cycle     4.55 x 10 <sup>-3</sup> .1.3 6 x 10 <sup>-2</sup> NOG, APP       Gene Expression     4.55 x 10 <sup>-3</sup> .1.3 6 x 10 <sup>-2</sup> NOG, APP       Immune Response     4.55 x 10 <sup>-3</sup> .1.3 6 x 10 <sup>-2</sup> OPRM1, PLA2G4A, ZNF354C, NOG, APP       Reproductive System Development     4.55 x 10 <sup>-3</sup> .1.3 6 x 10 <sup>-2</sup> OPRM1, PLA2G4A, ZNF354C, NOG, APP       Immune Response     4.55 x 10 <sup>-3</sup> .1.1 x 10 <sup>-2</sup> OPRM1, PLA2G4A, ZNF354C, NOG, APP       Viral Infection     4.55 x 10 <sup>-3</sup> .1.1 x 10 <sup>-2</sup> OPRM1, PLA2G4A, ZNF354C, NOG, APP       Immune Response     4.55 x 10 <sup>-3</sup> .1.1 x 10 <sup>-2</sup> NP       Organ Development     6.81 x 10 <sup>-3</sup> -1.06 x 10 <sup>-2</sup> NES       Infection     4.51 x 10 <sup>-3</sup> -9.07 x 10 <sup>-3</sup>	Gastrointestinal Disease	2.28 x10 <sup>-3</sup> -1.13 x10 <sup>-2</sup>	OPRM1, PLA2G4A
Metabolic Disease $2.28 \times 10^3 - 2.28 \times 10^3$ SCP2Nucleic Acid Metabolism $2.28 \times 10^3 - 1.13 \times 10^2$ SCP2, ACLYVitamin and Mineral Metabolism $2.28 \times 10^3 - 1.13 \times 10^2$ SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development $4.55 \times 10^3 - 1.36 \times 10^2$ PLA2G4A, NOG, APPCell Cycle $4.55 \times 10^3 - 1.36 \times 10^2$ APP, NR4A1Embryonic Development $4.55 \times 10^3 - 1.36 \times 10^2$ PARD3, PLA2G4A, ZNF354C, NOG, APPGene Expression $4.55 \times 10^3 - 1.36 \times 10^2$ OPRM1, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^3 - 1.36 \times 10^2$ VISS1, PLA2G4A, PDE4B, APPReproductive System Development $4.55 \times 10^3 - 1.36 \times 10^2$ APPOrgan Development $6.35 \times 10^3 - 0.75 \times 10^3$ NTF3, NOG, APPInfection $4.55 \times 10^3 - 1.36 \times 10^2$ APPOrgan Development $6.81 \times 10^3 - 6.81 \times 10^3$ APPInd Function $6.81 \times 10^3 - 9.07 \times 10^3$ NOGVisual System Development and Function $6.81 \times 10^3 - 9.07 \times 10^3$ NOGVisual System Development and Function $6.81 \times 10^3 - 1.26 \times 10^2$ NOGVisual System Development and Function $7.37 \times 10^3 - 7.37 \times 10^3$ NTF3, APPImmunological Disease $8.74 \times 10^3 - 1.26 \times 10^2$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^3 - 9.07 \times 10^3$ APPInmonological Disease $1.13 \times 10^2 - 1.13 \times 10^2$ APPInmonological Disease $1.13 \times 10^2 - 1.13 \times 10^2$ APPInmonological Disease $1.13 \times 10^2 $		2.28 x10 <sup>-3</sup> -1.41 x10 <sup>-2</sup>	OPRM1, PLA2G4A, PDE4B, APP
Nucleic Acid Metabolism $2.28 \times 10^3 \cdot 1.13 \times 10^2$ SCP2, ACLYVitamin and Mineral Metabolism $2.28 \times 10^3 \cdot 1.13 \times 10^2$ SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development $4.55 \times 10^3 \cdot 1.36 \times 10^2$ PLA2G4A, NOG, APPCell Cycle $4.55 \times 10^3 \cdot 1.36 \times 10^2$ MOG, APPEmbryonic Development $4.55 \times 10^3 \cdot 1.36 \times 10^2$ NOG, APPImmune Response $4.55 \times 10^3 \cdot 1.36 \times 10^2$ PARD3, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^3 \cdot 1.36 \times 10^2$ OPRM1, PLA2G4A, PDE4B, APPViral Infection $4.55 \times 10^3 \cdot 1.36 \times 10^2$ KISS1, PLA2G4AOrgan Development $6.55 \times 10^3 \cdot 1.36 \times 10^2$ NTF3, NOG, APPInfection $6.51 \times 10^3 \cdot 9.07 \times 10^3$ NTF3, NOG, APPHair and Skin Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGInaul System Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGImmunological System $7.37 \times 10^3 \cdot 7.37 \times 10^3$ NTF3, APPImmunological Disease $8.74 \times 10^3 \cdot 1.36 \times 10^2$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^3 \cdot 9.07 \times 10^3$ APPImmunological Disease $8.74 \times 10^3 \cdot 1.36 \times 10^2$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^3 \cdot 9.07 \times 10^3$ APPInnor Morphology $1.13 \times 10^2 \cdot 1.31 \times 10^2$ APPInnor Morphology $1.35 \times 10^3 \cdot 9.07 \times 10^3$ APPInnor Adat Metabolism $1.36 \times 10^2 \cdot 1.31 \times 10^2$ APP	Inflammatory Disease	2.28 x10 <sup>-3</sup> -1.25 x10 <sup>-2</sup>	OPRM1, PLA2G4A, PDE4B, APP, NR4A1
Vitamia ad Mineral Metabolism $2.28 \times 10^3 \cdot 1.13 \times 10^2$ SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APPCardiovascular System Development $4.55 \times 10^3 \cdot 1.36 \times 10^2$ PLA2G4A, NOG, APPCell Cycle $4.55 \times 10^3 \cdot 1.36 \times 10^2$ APP, NR4A1Embryonic Development $4.55 \times 10^3 \cdot 1.36 \times 10^2$ NOG, APPGene Expression $4.55 \times 10^3 \cdot 1.36 \times 10^2$ PARD3, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^3 \cdot 1.36 \times 10^2$ OPRM1, PLA2G4A, PDE4B, APPReproductive System Development $4.55 \times 10^3 \cdot 1.36 \times 10^2$ KISS1, PLA2G4AInfection $4.55 \times 10^3 \cdot 1.36 \times 10^2$ APPOrgan Development $6.35 \times 10^3 \cdot 9.07 \times 10^3$ NTF3, NOG, APPIndocrine System Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGHair and Skin Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGVisual System Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGVisual System Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGVisual System Development $6.81 \times 10^3 \cdot 9.07 \times 10^3$ NOGImmunological Disease $8.74 \times 10^3 \cdot 1.36 \times 10^2$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^3 \cdot 9.07 \times 10^3$ APPImmunological Disease $8.74 \times 10^3 \cdot 9.07 \times 10^3$ APPIndocrine System Disorders $1.13 \times 10^2 \cdot 1.13 \times 10^2$ APPImmunological Disease $8.74 \times 10^3 \cdot 9.07 \times 10^3$ APPIndocrine System Disorders $1.13 \times 10^2 \cdot 1.13 \times 10^2$ APPIndocrine System Disorders $1.13 \times 10^2 \cdot 1.13 \times 10^2$ APP<	Metabolic Disease	2.28 x10 <sup>-3</sup> -2.28 x10 <sup>-3</sup>	SCP2
Cardiovascular System Development and Function $4.55 \times 10^{-3} \cdot 1.36 \times 10^{-2}$ PLA2G4A, NOG, APPCell Cycle $4.55 \times 10^{-3} \cdot 1.36 \times 10^{-2}$ APP, NR4A1Embryonic Development $4.55 \times 10^{-3} \cdot 1.36 \times 10^{-2}$ NOG, APPGene Expression $4.55 \times 10^{-3} \cdot 1.36 \times 10^{-2}$ PARD3, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^{-3} \cdot 1.36 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APPReproductive System Development and Function $4.55 \times 10^{-3} \cdot 1.36 \times 10^{-2}$ KISS1, PLA2G4AViral Infection $4.55 \times 10^{-3} \cdot 1.36 \times 10^{-2}$ APPOrgan Development and Function $6.35 \times 10^{-3} \cdot 0.7 \times 10^{-3}$ NTF3, NOG, APPHair and Skin Development and Function $6.81 \times 10^{-3} \cdot 6.81 \times 10^{-3}$ APPVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGRenal and Urological System Development and Function $7.37 \times 10^{-3} - 7.37 \times 10^{-3}$ NTF3, APPImmunological Disease $8.74 \times 10^{-3} - 1.26 \times 10^{-2}$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^{-3} - 9.07 \times 10^{-3}$ APPEndocrine System Disorders $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APPTumor Morphology $1.13 \times 10^{-2} - 1.36 \times 10^{-2}$ APPAmino Acid Metabolism $1.36 \times 10^{-2} - 1.36 \times 10^{-2}$ APP	Nucleic Acid Metabolism	2.28 x10 <sup>-3</sup> -1.13 x10 <sup>-2</sup>	SCP2, ACLY
and Function $4.35 \times 10^{-1} - 1.36 \times 10^{-1}$ PLA204A, NOG, APPCell Cycle $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ APP, NR4A1Embryonic Development $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ NOG, APPGene Expression $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ PARD3, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APPReproductive System Development and Function $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ KISS1, PLA2G4AViral Infection $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ APPOrgan Development and Function $6.55 \times 10^{-3} - 1.31 \times 10^{-2}$ APPImdecrine System Development and Function $6.81 \times 10^{-3} - 6.81 \times 10^{-3}$ NTF3, NOG, APPEndocrine System Development and Function $6.81 \times 10^{-3} - 6.81 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGRenal and Urological System Development and Function $7.37 \times 10^{-3} - 7.37 \times 10^{-3}$ NTF3, APPImmunological Disease $8.74 \times 10^{-3} - 1.26 \times 10^{-2}$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^{-3} - 9.07 \times 10^{-3}$ APPEndocrine System Disorders $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APPTumor Morphology $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APPAmino Acid Metabolism $1.36 \times 10^{-2} - 1.36 \times 10^{-2}$ APP	Vitamin and Mineral Metabolism	2.28 x10 <sup>-3</sup> -1.13 x10 <sup>-2</sup>	SCP2, KISS1, PROKR2, OPRM1, NTF3, ACLY, OPRS1, ITPR1, APP
Embryonic Development $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ NOG, APPGene Expression $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ PARD3, PLA2G4A, ZNF354C, NOG, APPImmune Response $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APPReproductive System Development $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ KISS1, PLA2G4AViral Infection $4.55 \times 10^{-3} - 1.13 \times 10^{-2}$ APPOrgan Development $6.35 \times 10^{-3} - 9.07 \times 10^{-3}$ NTF3, NOG, APPEndocrine System Development $6.81 \times 10^{-3} - 9.07 \times 10^{-3}$ APPHair and Skin Development $6.81 \times 10^{-3} - 9.07 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 9.07 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGRenal and Urological System Development and Function $7.37 \times 10^{-3} - 7.37 \times 10^{-3}$ NTF3, APPImmunological Disease $8.74 \times 10^{-3} - 1.26 \times 10^{-2}$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^{-2} - 9.07 \times 10^{-3}$ APPIndocrine System Disorders $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APPInmonological Disease $8.74 \times 10^{-3} - 1.26 \times 10^{-2}$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^{-3} - 9.07 \times 10^{-3}$ APPInmonological Disease $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APPInmonological Disease $1.36 \times 10^{-2} - 1.13 \times 10^{-2}$ APPInmonological Disease $1.36 \times 10^{-2} - 1.13 \times 10^{-2}$ APPInmonological Disease <td></td> <td>4.55 x10<sup>-3</sup>-1.36 x10<sup>-2</sup></td> <td>PLA2G4A, NOG, APP</td>		4.55 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	PLA2G4A, NOG, APP
Gene Expression4.55 x10 <sup>3</sup> -1.36 x10 <sup>2</sup> PARD3, PLA2G4A, ZNF354C, NOG, APPImmune Response4.55 x10 <sup>3</sup> -1.41 x10 <sup>2</sup> OPRM1, PLA2G4A, PDE4B, APPReproductive System Development and Function4.55 x10 <sup>3</sup> -1.36 x10 <sup>2</sup> KISS1, PLA2G4AViral Infection4.55 x10 <sup>3</sup> -1.13 x10 <sup>2</sup> APPOrgan Development6.35 x10 <sup>3</sup> -9.07 x10 <sup>3</sup> NTF3, NOG, APPEndocrine System Development and Function6.81 x10 <sup>3</sup> -6.81 x10 <sup>3</sup> APPImmuno Skin Development and Function6.81 x10 <sup>3</sup> -9.07 x10 <sup>3</sup> NOGVisual System Development and Function6.81 x10 <sup>3</sup> -1.36 x10 <sup>2</sup> NOGVisual System Development and Function6.81 x10 <sup>3</sup> -1.36 x10 <sup>2</sup> NOGVisual System Development and Function7.37 x10 <sup>-3</sup> .7.37 x10 <sup>-3</sup> NTF3, APPPost-Translational Modification9.07 x10 <sup>-3</sup> .9.07 x10 <sup>-3</sup> APPInmunological Disease8.74 x10 <sup>-3</sup> -1.26 x10 <sup>2</sup> OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification9.07 x10 <sup>-2</sup> .1.13 x10 <sup>2</sup> APPInmor Morphology1.13 x10 <sup>2</sup> -1.13 x10 <sup>2</sup> APPTumor Morphology1.13 x10 <sup>2</sup> -1.13 x10 <sup>2</sup> APPTumor Acid Metabolism1.36 x10 <sup>2</sup> -1.36 x10 <sup>2</sup> APP	Cell Cycle	4.55 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	APP, NR4A1
Immune Response $4.55 \times 10^{-3} - 1.41 \times 10^{-2}$ OPRM1, PLA2G4A, PDE4B, APPReproductive System Development $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ KISS1, PLA2G4Aand Function $4.55 \times 10^{-3} - 1.13 \times 10^{-2}$ APPOrgan Development $6.35 \times 10^{-3} - 9.07 \times 10^{-3}$ NTF3, NOG, APPEndocrine System Development $6.81 \times 10^{-3} - 6.81 \times 10^{-3}$ APPHair and Skin Development and Function $6.81 \times 10^{-3} - 9.07 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 9.07 \times 10^{-3}$ NOGVisual System Development and Function $7.37 \times 10^{-3} - 7.37 \times 10^{-3}$ NTF3, APPImmunological Disease $8.74 \times 10^{-3} - 1.36 \times 10^{-2}$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^{-3} - 9.07 \times 10^{-3}$ APPEndocrine System Disorders $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APPTumor Morphology $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APPAmino Acid Metabolism $1.36 \times 10^{-2}$ APP	Embryonic Development	4.55 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	NOG, APP
Reproductive System Development and Function $4.55 \times 10^{-3} - 1.36 \times 10^{-2}$ KISS1, PLA2G4AViral Infection $4.55 \times 10^{-3} - 1.13 \times 10^{-2}$ APPOrgan Development $6.35 \times 10^{-3} - 9.07 \times 10^{-3}$ NTF3, NOG, APPEndocrine System Development and Function $6.81 \times 10^{-3} - 6.81 \times 10^{-3}$ APPHair and Skin Development and Function $6.81 \times 10^{-3} - 9.07 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGRenal and Urological System Development and Function $7.37 \times 10^{-3} - 7.37 \times 10^{-3}$ NTF3, APPImmunological Disease $8.74 \times 10^{-3} - 1.26 \times 10^{-2}$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^{-3} - 9.07 \times 10^{-3}$ APPIumor Morphology $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ NR4A1Amino Acid Metabolism $1.36 \times 10^{-2} - 1.36 \times 10^{-2}$ APP	Gene Expression	4.55 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	PARD3, PLA2G4A, ZNF354C, NOG, APP
and Function4.33 x104.33 x10AISSI, PLA2G4AViral Infection4.55 x10 <sup>-3</sup> -1.13 x10 <sup>-2</sup> APPOrgan Development6.35 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> NTF3, NOG, APPEndocrine System Development and Function6.81 x10 <sup>-3</sup> -6.81 x10 <sup>-3</sup> APPHair and Skin Development and Function6.81 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> NOGVisual System Development and Function6.81 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> NOGVisual System Development and Function6.81 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup> NOGRenal and Urological System Development and Function7.37 x10 <sup>-3</sup> -7.37 x10 <sup>-3</sup> NTF3, APPImmunological Disease8.74 x10 <sup>-3</sup> -1.26 x10 <sup>-2</sup> OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification9.07 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> APPEndocrine System Disorders1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> APPTumor Morphology1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> APP	Immune Response	4.55 x10 <sup>-3</sup> -1.41 x10 <sup>-2</sup>	OPRM1, PLA2G4A, PDE4B, APP
Organ Development6.35 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> NTF3, NOG, APPEndocrine System Development and Function6.81 x10 <sup>-3</sup> -6.81 x10 <sup>-3</sup> APPHair and Skin Development and Function6.81 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> NOGVisual System Development and Function6.81 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup> NOGRenal and Urological System Development and Function7.37 x10 <sup>-3</sup> -7.37 x10 <sup>-3</sup> NTF3, APPImmunological Disease8.74 x10 <sup>-3</sup> -1.26 x10 <sup>-2</sup> OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification9.07 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> APPEndocrine System Disorders1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> NR4A1Tumor Morphology1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> NR4A1		4.55 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	KISS1, PLA2G4A
Endocrine System Development and Function $6.81 \times 10^{-3} - 6.81 \times 10^{-3}$ APPHair and Skin Development and Function $6.81 \times 10^{-3} - 9.07 \times 10^{-3}$ NOGVisual System Development and Function $6.81 \times 10^{-3} - 1.36 \times 10^{-2}$ NOGRenal and Urological System Development and Function $7.37 \times 10^{-3} - 7.37 \times 10^{-3}$ NTF3, APPImmunological Disease $8.74 \times 10^{-3} - 1.26 \times 10^{-2}$ OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification $9.07 \times 10^{-3} - 9.07 \times 10^{-3}$ APPEndocrine System Disorders $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ NR4A1Amino Acid Metabolism $1.36 \times 10^{-2} - 1.36 \times 10^{-2}$ APP	Viral Infection	4.55 x10 <sup>-3</sup> -1.13 x10 <sup>-2</sup>	APP
and Function6.81 x10 <sup>-</sup> -6.81 x10 <sup>-</sup> APPHair and Skin Development and Function6.81 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> NOGVisual System Development and Function6.81 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup> NOGRenal and Urological System Development and Function7.37 x10 <sup>-3</sup> -7.37 x10 <sup>-3</sup> NTF3, APPImmunological Disease8.74 x10 <sup>-3</sup> -1.26 x10 <sup>-2</sup> OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification9.07 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> APPEndocrine System Disorders1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> APPTumor Morphology1.13 x10 <sup>-2</sup> -1.36 x10 <sup>-2</sup> NR4A1Amino Acid Metabolism1.36 x10 <sup>-2</sup> -1.36 x10 <sup>-2</sup> APP	Organ Development	6.35 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup>	NTF3, NOG, APP
Function6.81 x10 <sup>-2</sup> -9.07 x10 <sup>-3</sup> NOGVisual System Development and Function6.81 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup> NOGRenal and Urological System Development and Function7.37 x10 <sup>-3</sup> -7.37 x10 <sup>-3</sup> NTF3, APPImmunological Disease8.74 x10 <sup>-3</sup> -1.26 x10 <sup>-2</sup> OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification9.07 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> APPEndocrine System Disorders1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> APPTumor Morphology1.13 x10 <sup>-2</sup> -1.36 x10 <sup>-2</sup> NR4A1Amino Acid Metabolism1.36 x10 <sup>-2</sup> -1.36 x10 <sup>-2</sup> APP		6.81 x10 <sup>-3</sup> -6.81 x10 <sup>-3</sup>	APP
and Function6.81 x10 - 1.36 x10NOGRenal and Urological System Development and Function7.37 x10 <sup>-3</sup> -7.37 x10 <sup>-3</sup> NTF3, APPImmunological Disease8.74 x10 <sup>-3</sup> -1.26 x10 <sup>-2</sup> OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification9.07 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup> APPEndocrine System Disorders1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> APPTumor Morphology1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> NR4A1Amino Acid Metabolism1.36 x10 <sup>-2</sup> -1.36 x10 <sup>-2</sup> APP	1	6.81 x10 <sup>-3</sup> -9.07 x10 <sup>-3</sup>	NOG
Development and Function7.37 x10°-7.37 x10°NTP3, APPImmunological Disease8.74 x10°-1.26 x10°OPRM1, PLA2G4A, ITPR1, NR4A1Post-Translational Modification9.07 x10°-3.9.07 x10°APPEndocrine System Disorders1.13 x10°2-1.13 x10°APPTumor Morphology1.13 x10°2-1.13 x10°NR4A1Amino Acid Metabolism1.36 x10°2-1.36 x10°APP		6.81 x10 <sup>-3</sup> -1.36 x10 <sup>-2</sup>	NOG
Post-Translational Modification $9.07 \times 10^{-3} - 9.07 \times 10^{-3}$ APP     Endocrine System Disorders $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ APP     Tumor Morphology $1.13 \times 10^{-2} - 1.13 \times 10^{-2}$ NR4A1     Amino Acid Metabolism $1.36 \times 10^{-2} - 1.36 \times 10^{-2}$ APP		7.37 x10 <sup>-3</sup> -7.37 x10 <sup>-3</sup>	NTF3, APP
Endocrine System Disorders   1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> APP     Tumor Morphology   1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> NR4A1     Amino Acid Metabolism   1.36 x10 <sup>-2</sup> -1.36 x10 <sup>-2</sup> APP	Immunological Disease	8.74 x10 <sup>-3</sup> -1.26 x10 <sup>-2</sup>	OPRM1, PLA2G4A, ITPR1, NR4A1
Tumor Morphology   1.13 x10 <sup>-2</sup> -1.13 x10 <sup>-2</sup> NR4A1     Amino Acid Metabolism   1.36 x10 <sup>-2</sup> -1.36 x10 <sup>-2</sup> APP	Post-Translational Modification		APP
Amino Acid Metabolism $1.36 \times 10^{-2}$ $APP$	Endocrine System Disorders		APP
	Tumor Morphology		NR4A1
Organismal Survival 1.41 x10 <sup>-2</sup> -1.41 x10 <sup>-2</sup> GABRB3, NTF3, SV2A, NOG, ACLY, APP	Amino Acid Metabolism		APP
	Organismal Survival	1.41 x10 <sup>-2</sup> -1.41 x10 <sup>-2</sup>	GABRB3, NTF3, SV2A, NOG, ACLY, APP

Both of these are highly similar to the known miRNA rnomiR-297. These miRNAs may be validated in the future and added to the list of known rat miRNA sequences.

The targets of miRNA X, Y and Z have various neurological functions (Table 3 and 4). Hence, these

molecules may play various roles, while being regulated by the putative miRNA after exercise, in carrying out the function of the hippocampus of long-term memory and spatial navigation. Exercise and miRNA may also have implications on neurological disorders like Alzheimer's disease, as the hippocampus is often the first part of the brain to suffer cell death in affected individuals. Possible means of action of some molecules, under the influence of miRNAs, are presented in the sections that follow.

#### Gene Network (Interactome) Analysis

#### **MiRNA X Target Genes**

One of the top biological functions of target genes of this miRNA is nervous system function and development (Table 3). Thus, miRNA X may play a key role in neuregulin signaling, since its target genes are involved in this process. Neuregulin has been reported to induce reduction of NMDA (N-methyl-D-aspartate) receptor currents (Gu et al. 2005). Thus, decreased activity of the target gene Dlg4 due to increased miRNA X (discs, large homolog 4, Drosophila) in neuregulin signaling would result in increased NMDA receptor currents. This is consistent with increased Ca<sup>2+</sup> (which passes through NMDA receptors) during physical exercise. Elevated passing of  $Ca^{2+}$  ions through the NMDA receptor, according to Maruoka et al. (2000), leads to neuronal death. However, they emphasized that the presence of PSD95 (postsynaptic density-95; not found in the network) protein linked with an NMDA receptor is essential for this particular signaling.

Another important gene in the molecular network is Gria2 (glutamate receptor 2). Gria2 has a positive effect on the brain by reducing long-term synaptic depression, regulated by low levels of hippocampal estradiol during physical exercise. Reza Zamani et al. (2000) reported that high estradiol levels induce long-term synaptic depression by lowering the frequency threshold for LTD. Thus, low levels of estradiol, and the down-regulation of the Gria2 target gene by miRNA X, help maintain a high frequency threshold for LTD. It has yet to be experimentally determined, however, if Gria2 is regulated by exercise.

# **MiRNA Y and Z Target Genes**

The top biological functions of miRNA Y and Z targets include neurological disease and nervous system development and function (Table 4). IPA has shown that these targets interact with kinases (MAPKs) (Figure 3B) to produce a cascade of interactions among the major molecules in the network. These may have possible implications on neuron growth and differentiation in the hippocampus, as well as the progression of neurogeneretative diseases like Alzheimer's disease (AD).

Mitogen-activated protein kinases or MAPKs (includes Mapk, p38, and Mek), when activated through phosphorylation, participate in signal transduction pathways that control intracellular events including acute

responses to hormones and major developmental changes in organisms (Pearson et al. 2001; Ji & Suter 2007). Such phosphorylation of Mapk in oligodendrocyte progenitors and oligodendrocytes is induced by Nerve growth factor and Neurotrophin-3 (Ntf3, a target for miRNA Y and Z) (Cohen et al. 1996). This is apparent in Figure 3B. Ntf3 has been reported to help support the survival and differentiation of existing neurons, encourage the growth and differentiation of new neurons and synapses, and play a role in the regulation of glial development in the CNS (Maisonpierre et al. 1990). The activation of Mapk by Ntf3 in oligodendrocytes might lead to the proliferation of this type of neuron. Since miRNA Y and Z were shown to be down-regulated as a result of physical exercise, their targets would then be up-regulated. Ntf3 up-regulation would mean increased neuron growth and differentiation and increased MAPK activity.

App, the gene which codes for amyloid precursor protein (APP), is another potential target gene that interacts with the different kinases and proteins within the network. APP is a membrane-spanning protein that is the source of the amyloid-beta (A $\beta$ ) peptide of neuritic plaques in Alzheimer's disease (AD). AD has been identified as a protein misfolding disease due to the accumulation of an abnormally folded product of APP or hyperphosphorylation of tau ( $\tau$ ) proteins in the brain (Hashimoto et al. 2003). It is in the hippocampus of affected individuals where damage to the brain is first seen.

LeBlanc et al. (1998) have shown that APP processing can be controlled by Protein kinase c (Pkc) through the nonamyloidogenic pathway to produce the neuroprotective sAPP $\alpha$ . This APP-Pkc connection is evident in the molecular network in Figure 3B. Relating this to exercise, it has been shown that physical exercise contributes to increased Pkc activity (Heled et al. 2003). Therefore, as a consequence of physical exercise, putative novel miRNA Y and Z would be down-regulated, resulting in the possible up-regulation of the App gene. Consequently, Pkc activity is also increased during physical exercise, favoring the accumulation of sAPP $\alpha$ , the neurotrophic and neuroprotective product.

That exercise can be effective in ameliorating the effects of AD is not new, for example, a study by Adlard et al. (2005) showed that physical exercise can function as a simple behavioral intervention sufficient to inhibit the normal progression of AD. They used a genetically modified strain of mice (TgCRND8) exhibiting AD-like pathology and examined the interaction of physical exercise with the AD cascade. Long-term physical exercise showed enhanced learning of TgCRND8 animals in a maze, with significant reductions in escape latencies over the first three (of six) trial days.

However, Greenberg and colleagues (1994) showed that the sAPP $\alpha$  fragment of APP can potently stimulate Mapk to phosphorylate  $\tau$  in the brain. Many kinases can phosphorylate  $\tau$  in vitro, but MAPKs are among the likeliest to do so in vivo. Persistent activation of Mapk by sAPP $\alpha$  (through mutations in the App gene) could increase phosphorylation of  $\tau$  as well as other cellular elements, ultimately leading to the loss of cytoskeletal integrity and synaptic death, which are characteristics of AD. These studies suggest that the up-regulation of the App gene (through down-regulation of miRNA Y and Z because of physical exercise) to produce sAPP $\alpha$  would then present seemingly problematic results presenting us the limitation of bioinformatic analysis.

The IPA network functions only to display which of the genes possess established interactions with one another and it does not report which of these interactions are dominant. Considering that, we cannot verify whether the physical exercise regimen of the rats was indeed sufficient to induce increased Pkc activity resulting in production of sAPP $\alpha$  or to produce enough sAPP $\alpha$  to stimulate Mapks to phosphorylate  $\tau$ . Further experiments with the sAPP $\alpha$  product of App and its role on the pathways of Mapk and Pkc would provide more information on how this secretory product works as a neuroprotective agent and how it can also contribute to the increased phosphorylation of  $\tau$ , which is one of the landmarks of AD.

#### **Final Remarks**

Computational approaches in determining expressed microRNAs from the rat hippocampi during physical exercise can open doors for discovering other mechanisms of how physical exercise improves brain function. The IPA generated networks show us possible key points for intervention of the potential novel miRNAs, provided that they are expressed as a result of physical exercise. Moreover, since most up-regulated target genes are involved in neuron growth and differentiation, the possibility that physical exercise can be involved in enhancing memory and learning can be explored.

# ACKNOWLEDGMENT

The authors acknowledge the support of the AIST's Brain Stress Research Group: Randeep Rakwal, Junko Shibato, Yoshinori Masuo and Misato Hirano for the microarray data; Hideaki Soya, Takeshi Nishijima, Yuhei Yamamura, Masahiro Okamoto, Akiyo Kimpara, Miho Iimura and Takashi Matsui of Tsukuba University's Institute for Health & Sports Sciences for technical advice and expert assistance with animal care and experiments. This study is recognized by Mensa Philippines.

# REFERENCES

- ADLARD PA, PERREAU VM, POP V, COTMAN CW. 2005. Voluntary Exercise Decreases Amyloid Load in a Transgenic Model of Alzheimer's disease. J Neurosci 25 (17):4217–4221.
- AMBROS V, BARTEL B, BARTEL DP, BURGE CB, CARRINGTON JC, CHEN X, DREYFUSS G, EDDY SR, GRIFFTHS-JONES S, MARSHALL A. 2003. A uniform system for microRNA annotation. RNA 9:277–279.
- CAVALLARO S, D'AGATA V, MANICKAM P, DUFOUR F, ALKON DL. 2002. Memory specific temporal profiles of gene expression in the hippocampus. Proc Natl Acad Sci 99(25): 16279-16284.
- COHEN RI, MARMUR R, NORTON WT, MEHLER MF, KESSLER JA. 1996. Nerve Growth Factor and Neurotrophin-3 Differentially Regulate the Proliferation and Survival of Developing Rat Brain Oligodendrocytes. J Neurosci 16 (20):6433–6442.
- COLCOMBE SJ, ERICKSON KI, SCALF PE, KIM JS, PRAKASH R, MCAULEY E, ELAVSKY S, MARQUEZ DX, HU L, KRAMER AF. 2006. Aerobic Exercise Training Increases Brain Volume in Aging Humans. J Gerontol A Biol Sci Med Sci (61):1166-1170.
- ETNIER J, SALAZAR W, LANDERS D, PETRUZELLO S, HAN M, NOWELL P. 1997. The Influence of Physical Fitness and Exercise upon Cognitive Functioning: A Meta- Analysis. JSEP 19 (3).
- GREENBERG SM, KOO EH, SELKOE DJ, QIU WQ, KOSIK KS. 1994. Secreted 1- amyloid precursor protein stimulates mitogen-activated protein kinase and enhances  $\tau$  phosphorylation. Proc Nat Acad Sci 91:7104-7108.
- GRIFFITHS-JONES S. 2003. The microRNA Registry. Nucleic Acid Research 32 (Database issue):D109– D111.
- GU Z, JIANG Q, FU AKY, IP NY, YAN Z. 2005. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci 25 (20):4974-4984.
- HASHIMOTO M, ROCKENSTEIN E, CREWS L, MASLIAH E. 2003. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases. Neuromolecular Med 4 (1-2):21-36.
- HELED Y, SHAPIRO Y, SHANI Y, MORAN DS, LANGZAM L, BRAIMAN L, SAMPSON SR,

MEYEROVITCH J. 2003. Physical exercise enhances protein kinase C  $\delta$  activity and insulin receptor tyrosine phosphorylation in diabetes-prone Psammomys obesus. Metabolism 52 (8):1028-1033.

- HILLMAN CH, MOTL RW, PONTIFEX MB, POSTHUMA D, STUBBE JH, BOOMSMA DI, DE GEUS EJC. 2006. Physical Activity and Cognitive Function in a Cross-Section of Younger and Older Community Dwelling Individuals. Health Psychol 25 (6):678-687.
- HIRANO M, RAKWAL R, SHIBATO J, SAWA H, NAGASHIMA K, OGAWA Y, YOSHIDA Y, IWAHASHI H, NIKI E, MASUO Y. 2008. Proteomicsand transcriptomics-based screening of differentially expressed proteins and genes in brain of Wig rat: a model for attention deficit hyperactivity disorder (ADHD) research. J Proteome Res 7(6):2471-689.
- INGENUITY SYSTEMS. 2006. Ingenuity pathway analysis network generation. Retrieved December 2007 from http://analysis.ingenuity.com.
- INGENUITY PATHWAYS ANALYSIS. 2006. (Windows Version 5.5) [Computer Program]. Available distributor: Ingenuity Systems, Redwood, CA.
- JI RR, SUTER MR. 2007. p38 MAPK, microglial signaling, and neuropathic pain. Mol Pain 3 (33).
- KEMPER HCG, BAKKER I, VAN TULDER MW, KOSTENSE PJ, COURTEIX D. 2000. Exercise for preventing low bone mass in young males and females. Cochrane Database of Systematic Reviews: Protocols, Issue 3. Chichester, UK: John Wiley & Sons, Ltd. CD002264.
- LAI EC, TOMANCAK P, WILLIAMS RW, RUBIN GM. 2003. Computational identification of Drosophila microRNA genes. Genome Biol 4 (7):R:42.
- LEBLANC AC, KOUTROUMANIS M, GOODYER CG. 1998. Protein Kinase C Activation Increases Release of Secreted Amyloid Precursor Protein without Decreasing Ab Production in Human Primary Neuron Cultures. J Neurosci 18 (8):2907–2913.
- LI SC, PAN CY, LIN W. 2006. Bioinformatic discovery of microRNA precursors from human ESTs and introns. BMC Genomics 7:164.
- MAISONPIERRE PC, BELLUSCIO L, SQUINTO S, IP NY, FURTH ME, LINDSAY RM, YANCOPOULOS GD. 1990. Neurotrophin-3: a neurotrophic factor related to NGF and BDNF. Science 247 (4949, Pt. 1):1446-1451.
- MARUOKA H, KITAOKA S, TOHNAI N, INAKI Y,

HATAE T, TANABE T. 2000. The behavior and effect of isopoly (S-carboxymethyl-L-cysteine) derivatives of nucleic acid bases. Nucleic Acids Symp Ser 44:195-196.

- MICROBASE TARGETS. 2006. microRNA listings for *Rattus norvegicus*. Retrieved on December 22, 2007 from http://microrna.sanger.ac.uk/cgi-bin/targets/v5/ search.ph.
- MOLTENI R, YING Z, GOMEZ-PINILLA F. 2002. Differential effects of acute and chronic exercise on plasticity-related genes in the rat hippocampus revealed by microarray. Eur J Neurosci 16 (6):1107-1116.
- [NCBI] NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION. 2004. ESTs: Gene Discovery Made Easier. Retrieved December 11, 2007 from http://www. ncbi.nlm.nih.gov/About/primer/est.html.
- PEARSON G, ROBINSON G, GIBSON TB, XU B, KARANDIKAR M, BERMAN K, COBB MH. 2001. Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions. Endocr Rev 22 (2):153-183.
- PREALL JB, HE Z, GORRA JM, SONTHEIMER EJ. 2006. Short interfering RNA strand selection is biogenesis and posttranscriptional gene silencing. Cell 123 (4):631-40.
- REZA ZAMANI M, DESMOND NL, LEVY WB. 2000. Estradiol Modulates Long-Term Synaptic Depression in Female Rat Hippocampus. J Neurophysiol 84:1800-1808.
- RUDD S. 2003. Expressed sequence tags: alternative or complement to whole genome sequences? Trends in Plant Sci 8 (7):321-329.
- UNIPROT. 2002. UniProt Knowledgebase. Retrieved on December 22, 2007 from http://beta.uniprot.org.
- VAN PRAAG H, CHRISTIE BR, SEJNOWSKI TJ, GAGE FH. 1999. Running enhances neurogenesis, learning and long-term potentiation in mice. Proc Nat Acad Sci 96(23):427–431.
- WELK GJ, BLAIR SN. 2000. Physical Activity Protects against the Health Risks of Obesity. President's Council on Physical Fitness and Sports: Res Digest 3 (12).
- ZHANG B, PAN X, ANDERSON TA. 2006. Identification of 188 conserved maize microRNAs and their targets. FEBS Lett 580:3753-3762.
- ZHANG BH, PAN XP, WANG QL, COBB GP, ANDERSON TA. 2005. Identification and characterization of new plant microRNAs using EST analysis. Cell Res 5 (5):336-360.

Philippine Journal of Science Vol. 139 No. 1, June 2010

- ZHANG Y, WOLTERING JM, VERBEEK FJ. 2007. Screen of microRNA targets in zebrafish using heterogenous data sources: a case study for dre-miR-10 and drej-miR-196. Int J Math Phys Engg Sci 2(1): 10-17.
- ZUKER M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31 (13):3406-15.
- ZUKER M, MATHEWS DH, SABINA J, TURNER DH. 1999. Expanded Sequence Dependence of Thermodynamic Parameters Improves Prediction of RNA Secondary Structure. J Mol Biol 288:911-940.